Surprisingly SMARCA4 mutations were mutually exclusive with the most prevalent, targeted oncogenes in NSCLC, including EGFR, ALK, MET, ROS1 and RET (P = 1.2E−34). This evidence concerns the gene ALK and non-small cell lung carcinoma.